NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 181 filers reported holding NEKTAR THERAPEUTICS in Q4 2015. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $23,000 | -32.4% | 1,417 | -3.5% | 0.00% | – |
| Q2 2020 | $34,000 | -39.3% | 1,469 | -44.2% | 0.00% | – |
| Q1 2020 | $56,000 | 0.0% | 2,634 | 0.0% | 0.00% | – |
| Q4 2019 | $56,000 | +19.1% | 2,634 | 0.0% | 0.00% | – |
| Q3 2019 | $47,000 | -49.5% | 2,634 | -0.2% | 0.00% | – |
| Q2 2019 | $93,000 | +5.7% | 2,638 | 0.0% | 0.00% | – |
| Q1 2019 | $88,000 | +2.3% | 2,638 | +0.2% | 0.00% | – |
| Q4 2018 | $86,000 | +258.3% | 2,634 | +430.0% | 0.00% | – |
| Q2 2018 | $24,000 | -7.7% | 497 | +11.4% | 0.00% | – |
| Q1 2018 | $26,000 | 0.0% | 446 | 0.0% | 0.00% | – |
| Q4 2017 | $26,000 | +2500.0% | 446 | +643.3% | 0.00% | – |
| Q3 2016 | $1,000 | -95.7% | 60 | -97.2% | 0.00% | – |
| Q3 2015 | $23,000 | -14.8% | 2,169 | 0.0% | 0.00% | – |
| Q2 2015 | $27,000 | +17.4% | 2,169 | 0.0% | 0.00% | – |
| Q1 2015 | $23,000 | -30.3% | 2,169 | 0.0% | 0.00% | – |
| Q4 2014 | $33,000 | – | 2,169 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |